[Can antiplatelet therapy be continued in upper gastrointestinal bleeding?]

Area of Science:

• Internal Medicine
• Cardiology
• Gastroenterology

Background:

• Antiplatelet agents are crucial for preventing thrombotic events.
• Gastrointestinal (GI) bleeding poses a significant risk in patients on antiplatelet therapy.
• Management decisions require balancing bleeding risk against thrombotic risk.

Purpose of the Study:

• To outline evidence-based strategies for managing antiplatelet therapy during gastrointestinal bleeding.
• To provide guidance on treatment resumption based on the indication for antiplatelet use.

Main Methods:

• Review of current clinical guidelines and expert recommendations.
• Analysis of risk-benefit profiles for antiplatelet therapy in different patient populations.

Main Results:

• In primary prevention, discontinuing antiplatelet agents is often appropriate due to limited benefit.
• For secondary prevention, a brief interruption (around five days) followed by resumption is generally recommended.
• Management in patients with coronary stents necessitates a personalized, multidisciplinary approach.

Conclusions:

• Antiplatelet therapy management during GI bleeding is indication-dependent.
• A collaborative approach involving multiple specialists is essential for optimal patient outcomes.
• Individualized treatment plans are critical, especially in high-risk patients.